Phaseline

Companies › Enanta Pharmaceuticals

Enanta Pharmaceuticals: clinical trials, targets and expected readouts

2 active drug programs in 3 registered trials: 2 Phase 2, 1 Phase 1; Immunology, Infectious disease, Respiratory; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Zelicapavir
RSV non-fusion replication inhibitor
RSVPhase 2RSV Infection; RSVDec 2026
EDP-978–Phase 1Chronic Inducible UrticariaNov 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07540910EDP-978Phase 1Chronic Inducible UrticariaImmunologyNov 2026
NCT07482657ZelicapavirPhase 2RSV InfectionInfectious diseaseDec 2026
NCT07908381ZelicapavirPhase 2RSVRespiratoryJul 2029

From the company's SEC filings

Cash and short-term investments of $190m on 2026-06-30; operating cash outflow about $39m a year; runway about 59 months at that burn, to May 2031; 2 of 2 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Specialist investors

Held by 2 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

RSV (1)

Companies with the same targets

Sanofi ModernaTX AstraZeneca MAXVAX Biotechnology Limited Liability Company Shenzhen Shenxin Biotechnology GSK

Companies built like this

Avalyn Pharma Sagimet Biosciences Thirty Respiratory Kymera Therapeutics Shanghai Longwood Biopharmaceuticals

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.